Features of the functional state of the pituitary-ovarian systems in women with polycystic ovary syndrome at different periods of reproductive age

Cover Page
Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract


Background. PCOS is one of the most common endocrinological pathologies in women of reproductive age, manifested by a wide range of clinical manifestations. There are many unresolved issues related to the pathogenesis, diagnosis and treatment of this pathological condition in different periods of reproductive age. Aim — the objective of the study was to identify the features of the functioning of the pituitary-ovarian system in women with PCOS at different periods of reproductive age. Methods. Study was performed in 2017–2019 at the FSPSI SCFHHRP, and involved women aged 18–45 years. The study groups included women (a group of women with PCOS and a control group) in the follicular phase from 1 to 12 days of the menstrual cycle. As a result of the survey, a group of 44 women with PCOS and a group of 56 healthy women were formed. PCOS was diagnosed according to ESHRE/ASRM criteria (Rotterdam, 2003). Next, subgroups of women in early reproductive age from 35 to 45 years were formed: a group of women with PCOS (n = 29) and a control group (n = 22). And groups of women in late reproductive age from 35 to 45 years were formed: a group of women with PCOS (n = 15) and a control group (n = 34). Conducted: questionnaire survey, general and gynecological examination, ultrasound examination of the pelvic organs, laboratory tests, statistical data analysis. Results. In women with polycystic ovary syndrome of early reproductive age (18–35 years), we detected an increase in the level of testosterone by 2 times, DHEA-S by 1.3 times, 17-OH-progesterone by 2 times, sex steroid-binding globulin by 1.4 times, in comparison with control group. The ratio of luteinizing hormone to follicle-stimulating hormone increased by 52%. In women with polycystic ovary syndrome of late reproductive age (35–45 years), we detected an increase in the level of testosterone by 1.5 times, 17-OH-progesterone by 1.9 times, luteinizing hormone by 1.4 times, sex steroid-binding globulin by 1.6 times, in comparison with control group, without any significant differences in DHEA-S. At the same time, the ratio of luteinizing hormone to follicle-stimulating hormone increased by 60%. Conclusion. The hormonal profile of women with PCOS of early and late reproductive period is characterized by series of age-related changes in the pituitary-ovarian system, which should be taken into account in preventive and therapeutic measures.


Full Text

Restricted Access

About the authors

O. V. Krusko

Scientific Centre for Family Health and Human Reproduction Problems

Author for correspondence.
Email: panarinaolya08@mail.ru
ORCID iD: 0000-0001-9111-7914
SPIN-code: 4702-6002

Russian Federation, Irkutsk

Junior Research Associate

L. F. Sholokhov

Scientific Centre for Family Health and Human Reproduction Problems

Email: lfshol@mail.ru
ORCID iD: 0000-0003-3588-6545
SPIN-code: 4138-8991

Russian Federation, Irkutsk

MD, PhD, Head of the Laboratory of Physiology and Pathology of the Endocrine System

L. V. Belenkaya

Scientific Centre for Family Health and Human Reproduction Problems

Email: Drblv@mail.ru
ORCID iD: 0000-0003-4730-5154
SPIN-code: 6272-2718

Russian Federation, Irkutsk

MD, PhD, Senior Research Associate

M. A. Rashidova

Scientific Centre for Family Health and Human Reproduction Problems

Email: stella-m90@mail.ru
ORCID iD: 0000-0003-4730-5154
SPIN-code: 1361-0840

Russian Federation, Irkutsk

PhD in Biology, Research Associate

I. N. Danusevich

Scientific Centre for Family Health and Human Reproduction Problems

Email: irinaemails@gmail.com
ORCID iD: 0000-0002-8862-5771
SPIN-code: 6289-3358

Russian Federation, Irkutsk

MD, PhD, Head of the Laboratory of Gynecological Endocrinology

Ya. G. Nadelyaeva

Scientific Centre for Family Health and Human Reproduction Problems

Email: ianadoc@mail.ru
ORCID iD: 0000-0002-5747-7315
SPIN-code: 7766-5841

Russian Federation, Irkutsk

PhD, Research Associate

L. М. Lazareva

Scientific Centre for Family Health and Human Reproduction Problems

Email: lirken_@mail.ru
ORCID iD: 0000-0002-7662-8529

Russian Federation, Irkutsk

MD, PhD, Research Associate

L. I. Kolesnikova

Scientific Centre for Family Health and Human Reproduction Problems

Email: iphr@sbamsr.irk.ru
ORCID iD: 0000-0003-3354-2992
SPIN-code: 1584-0281

Russian Federation, Irkutsk

MD, PhD, Professor, Academician of the RAS

References

  1. Никонова Л.В., Тишковский С.В., Бутрим О.С., Давыдчик Э.В. Клинико-гормональные варианты синдрома гиперандрогении // Журнал Гродненского государственного медицинского университета. — 2018. — Т. 16. — № 5. — С. 542–548. [Nikonova LV, Tishkovskij SV, Butrim OS, Davydchik EV. Kliniko-gormonal’nye varianty sindroma giperandrogenii. Zhurnal Grodnenskogo Gosudarstvennogo Medicinskogo Universiteta. 2018;16(5):542–548. (In Russ.)] doi: https://doi.org/10.25298/2221-8785-2018-16-5-542-548
  2. Rodgers RJ, Suturina L, Lizneva D, et al. Is polycystic ovary syndrome a 20th Century phenomenon? Med Hypotheses. 2019;124:31–34. doi: https://doi.org/10.1016/j.mehy.2019.01.019
  3. Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human Reproduction, 2018;33(9):1602–1618. doi: https://doi.org/10.1093/humrep/dey256
  4. Kolesnikova LI, Kolesnikov SI, Darenskaya MA, et al. Activity of LPO Processes in Women with Polycystic Ovarian Syndrome and Infertility. Bull Exp Biol Med. 2017;162:3:320–322. doi: https://doi.org/10.1007/s10517-017-3605-5
  5. Ding T, Hardiman PJ, Petersen IG, et al. The prevalenceof polycystic ovary syndrome in reproductive-aged women of different ethnicity: A systematic review and meta-analysis. Oncotarget. 2017;8:96351–96358. doi: https://doi.org/10.18632/oncotarget.19180
  6. Mehrabian F, Khani B, Kelishadi R, Ghanbari E. The prevalence of polycystic ovary syndrome in Iranian women based on different diagnostic criteria. Endokrynol Pol. 2011;62:238–242.
  7. Chen X, Yang D, Mo Y, et al. Prevalence of polycystic ovary syndrome in unselected women from southern China. Eur J Obstet Gynecol Reprod Biol. 2008;139:59–64. doi: https://doi.org/10.1016/j. ejogrb.2007.12.018
  8. Knochenhauer ES, Key TJ, Kahsar-Miller M, et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: A prospective study. J Clin Endocrinol Metab. 1998;83:3078–3082. doi: https://doi.org/10.1210/jcem.83.9.5090
  9. Gabrielli L, Aquino EML. Polycystic ovary syndrome in Salvador, Brazil: A prevalence study in primary healthcare. Reprod Biol Endocrinol. 2012;10:96. doi: https://doi.org/10.1186/1477-7827-10-96
  10. Li R, Zhang Q, Yang D, et al. Prevalence of polycystic ovary syndrome in women in China: A large community-based study. Hum Reprod. 2013;28:2562–2569. doi: https://doi.org/10.1093/humrep/det262
  11. Kumarapeli V, de Seneviratne RA, Wijeyaratne CN, et al. A simple screening approach for assessing community prevalence and phenotype of polycystic ovary syndrome in a Semiurban Population in Sri Lanka. Am J Epidemiol. 2008;168:321–328. doi: https://doi.org/10.1093/aje/kwn137
  12. Glintborg D, Hass Rubin K, Nybo M, et al. Morbidity and medicine prescriptions in a nationwide Danish population of patients diagnosed with polycystic ovary syndrome. Eur J Endocrinol. 2015;172:627–638. doi: https://doi.org/10.1530/EJE-14-1108
  13. Bozdag G, Mumusoglu S, Zengin D, et al. The prevalence and phenotypic features of polycystic ovary syndrome: A systematic review and meta-analysis. Hum Reprod. 2016;31:2841–2855. doi: https://doi.org/10.1093/humrep/dew218
  14. Varanasi LC, Subasinghe A, Jayasinghe YL, et al. Polycystic ovarian syndrome: Prevalence and impact on the wellbeing of Australian women aged 16–29 years. Aust N Z J Obstet Gynecol. 2018;58:222–233. doi: https://doi.org/10.1111/ajo.12730
  15. Дедов И.И., Мельниченко Г.А., Чеботникова Т.В., и др. Распространенность и клиническая картина синдрома поликистозных яичников в популяции Москвы // Проблемы эндокринологии. — 2010. — Т. 56. — № 4. — С. 3–8. [Dedov II, Mel’nichenko GA, Chebotnikova TV, et al. The prevalence and clinical features of polycystic ovary syndrome in a Moscow population. Problemy Endokrinologii. 2010;4(56):3–8. (In Russ.)]. doi: https://doi.org/10.14341/probl20105643-8
  16. Игнатко И.В., Швырёва Е.А., Лебедев В.А., и др. Тактика ведения преждевременных родов: кому показан и поможет токолиз // Архив акушерства и гинекологии им. В.Ф. Снегирева. — 2018. — Т. 5. — № 1. — С. 49–54. [Ignatko IV, Shvyreva EA, Lebedev VA., et al. Tactics of the management of premature deliveries: to what patients tocolysis is indicated and should help. Arhiv Akusherstva i Ginekologii im. V.F. Snegireva. 2018;1(5):49–54. (In Russ.)] doi: https://doi.org/10.18821/2313-8726-2018-5-1-49-54
  17. Сутурина Л.В. Синдром поликистозных яичников в XXI веке // Акушерство и генекология: новости, мнения, обучение. — 2017. — Т. 17. — № 3. — С. 86–91. [Suturina LV. Polycystic ovarian syndrome in the 21st century. Akusherstvo i Genekologiya: Novosti, Mneniya, Obuchenie. 2017;3(17):86–91. (In Russ.)]
  18. Pinola P, Puukka K, Piltonen T, et al. Normo- and hyperandrogenic women with polycystic ovary syndrome exhibit an adverse metabolic profile through life. Fertility and Sterility. 2017;107(3):1–10. doi: https://doi.org/10.1016/j.fertnstert.2016.12.017
  19. Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr Rev. 2016;37(5):467–520. doi: https://doi.org/10.1210/er.2015-1104
  20. Lizneva D, Suturina L, Walker W, et al. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106(1):6–15. doi: https://doi.org/10.1016/j.fertnstert.2016.05.003
  21. Pugeat M, Plotton I, Brac A. Hyperandrogenic states in women: pitfalls in laboratory diagnosis. Eur J Endocrinol. 2018;178:4:142–154. doi: https://doi.org/10.1530/EJE-17-0776
  22. Иловайская И.А. Гиперандрогенные нарушения и заболевания женщин: дифференциальная диагностика и лечебная тактика // Доктор.Ру. — 2018. — Т. 150. — № 6. — С. 49–55. [Ilovaiskaya IA. Hyperandrogenic Disorders and Female Diseases: Differential Diagnosis and Treatment Approaches. Doctor.Ru. 2018;6(150):49–55. (In Russ.)] doi: https://doi.org/10.31550/1727-2378-2018-150-6-49-55
  23. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41–47. doi: https://doi.org/10.1093/humrep/deh098
  24. Naing L, Winn T, Rusli BN. Practical issues in calculating the sample size for prevalence studies. Med Stat. 2006;1:9–14.
  25. March W, Moore V, Willson K, et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010;25(2):544–551. doi: https://doi.org/10.1093/humrep/dep399
  26. Harris PA, Yaylor R, Thielke R, et al. Research electronic data capture (REDCap) — A Metadata-Driven Methodology and Workflow Process for Providing Translational Research Informatics Support. Journal of Biomedical Informatics. 2009;42(2):377–381. doi: https://doi.org/10.1016/j.jbi.2008.08.010
  27. Belenkaia LV, Lazareva LM, Walker W, et al. Criteria, phenotypes and prevalence of polycystic ovary syndrome. Minerva Ginecol. 2019;71(3):211–223. doi: https://doi.org/10.23736/S0026-4784.19.04404-6
  28. Varanasi LC, Subasinghe A, Jayasinghe YL, et al. Polycystic ovarian syndrome: Prevalence and impact on the wellbeing of Australian women aged 16–29 years. Aust N Z J Obstet Gynecol. 2018;58:222–233. doi: https://doi.org/10.1111/ajo.12730
  29. Солопова А.Г., Макацария А.Д., Солопова А.Е., Никифорова О.В. Склерокистозные яичники: современный взгляд на проблему // Акушерство, гинекология и репродуктология. — 2017. — Т. 11. — № 2. — С. 57–68. [Solopova AG, Makatsariya AD, Solopova AE, Nikiforova OV. Sclerocystic ovaries: current approaches to the proble. Akusherstvo, Ginekologiya i Reproduktologiya. 2017;1(28):57–68. (In Russ.)] doi: https://doi.org/10.17749/2313-7347.2017.11.2.057-068
  30. Колесникова Л.И., Корнакова Н.В., Лабыгина А.В., и др. Состояние гормонально-метаболических процессов у женщин с поликистозом яичников и бесплодием // Бюллетень СО РАМН. — 2008. — Т. 28. — № 1. — С. 21–25. [Kolesnikova LI, Kornakova NV, Labigina AV, et al. Hormonal-metabolic processes condition of women with polycystic ovaries and infertility. Byulleten’ SO RAMN. 2008;28(1):21–25. (In Russ.)]
  31. Гончаров Н.П., Кация Г.В. Нейростероид дегидро- эпиандростерон и функции мозга // Физиология человека. — 2013. — Т. 39. — № 6. — С. 120–128. [Goncharov NP, Katsya GV. Neurosteroid denydroepiandrosterone and brain function. Human Physyology. 2013;39(6):120–128. (In Russ.)] doi: 10.1134/S036211971304004X
  32. Carvalho LML, Dos Reis FM, Candido AL, et al. Polycystic Ovary Syndrome as a systemic disease with multiple molecular pathways: a narrative review. Endocr Regul. 2018;52(4):208–221. doi: https://doi.org/10.2478/enr-2018-0026

Supplementary files

There are no supplementary files to display.

Statistics

Views

Abstract - 93

PDF (Russian) - 1

Cited-By


Article Metrics

Metrics Loading ...

PlumX

Dimensions



Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies